Research Article

Sexual Dimorphisms of Adrenal Steroids, Sex Hormones, and Immunological Biomarkers and Possible Risk Factors for Developing Rheumatoid Arthritis

Alfonse T. Masi,1 Azeem A. Rehman,2 Laura C. Jorgenson,2 Jennifer M. Smith,2 and Jean C. Aldag2

1Department of Medicine, University of Illinois College of Medicine at Peoria (UICOMP), One Illini Drive, Peoria, IL 61656, USA
2University of Illinois College of Medicine at Peoria, Peoria, IL 61656, USA

Correspondence should be addressed to Alfonse T. Masi; amasi@uic.edu

Received 11 September 2015; Accepted 27 October 2015

Academic Editor: Vincenzo Brancaleone

Copyright © 2015 Alfonse T. Masi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Innate immunity and immunological biomarkers are believed to be interrelated with sex hormones and other neuroendocrine factors. Sexual dimorphism mechanisms may be operating in certain rheumatic and inflammatory diseases which occur more frequently in women than men, as rheumatoid arthritis (RA). Less data have been available on altered interrelations of the combined neuroendocrine and immune (NEI) systems as risk factors for development of certain diseases. In this study, serological interrelations of NEI biomarkers are analyzed before symptomatic onset of RA (pre-RA) versus control (CN) subjects, stratified by sex. Sexual dimorphism was found in serum levels of acute serum amyloid A (ASAA), soluble interleukin-2 receptor alpha (sIL-2R𝛼), and soluble tumor necrosis factor receptor 1 (sTNF-R1). Multiple steroid and hormonal (neuroendocrine) factors also showed highly significant sexual dimorphism in their assayed values, but less for cortisol (𝑝=0.012), and not for 17-hydroxyprogesterone (𝑝=0.176). After stratification by sex and risk of developing RA, differential NEI correlational patterns were observed in the interplay of the NEI systems between the pre-RA and CN groups, which deserve further investigation.

1. Introduction

Clinical experimental [1–3] and prospective epidemiological studies [4] suggest that dysregulation of adrenocortical or gonadal function may predispose to developing rheumatoid arthritis (RA). Serum adrenal androgen (AA) steroid levels were lower in a minority of women who had premenopausal onset of disease, compared to matched control (CN) females [2]. A greater minority of women who subsequently developed rheumatoid arthritis (pre-RA cases) had combined low serum cortisol and low androstenedione concentrations than matched cohort CN females [4]. Multicompartmental (multizonal) relative adrenocortical insufficiency was suspected in a minority subset of pre-RA women, which may predispose to developing the disease [4].

The immunological network, including serum acute phase proteins (APPs), inflammatory cytokines, their receptors, and antagonists, is integrated [5, 6]. Pro-inflammatory cytokine signaling activates APPs and also influences their receptor concentrations under complex biological systems control mechanisms during health and varied clinical diseases [5, 6]. Tumor necrosis factor-alpha (TNF-𝛼) and interleukin-6 (IL-6) are increased in chronic inflammatory diseases, like RA [7]. In a domestic cohort study [8], elevated serum C-reactive protein (CRP) levels (8+ mg/dL) were more frequently (𝑝=0.010) found in 8 (17.4%) of 46 pre-RA than in 9 (5.0%) of 179 CN subjects. In a separate case-control cohort study of blood donors in Netherlands [9], slightly higher median CRP concentrations were found in multiple serum samples from 79 pre-RA compared to 79 matched CN subjects. The differences were significant within a 5-year interval between serum testing and onset of clinical symptoms, but not in longer 1-year periods, extending to 15 years (median 7.5 years). Serum acute phase proteins, inflammatory cytokines, and other immunological components differ by age and sex and may be related to such host predispositions in
inflammatory diseases, like RA [8]. The aim of this study was to analyze a large community cohort database for relations of age and sex to both neuroendocrine and immunologic (NEI) biomarkers, particularly as they may relate to sexual dimorphism and predisposition to clinical onset of RA.

2. Methods

2.1. The RA Precursors Study (RAPS) Neuroendocrine Immune (NEI) Database. The RA Precursors Study (RAPS) was initiated at this institution in 1991 [4, 8, 10]. Baseline data and sera were donated by Operation CLUE I, a community-wide prospective study. A comprehensive serum neuroendocrine panel was assayed in a university referral laboratory on a community-based cohort of pre-RA and CN females in 1992 and 1994 [4] and on a male cohort of study subjects in 1996 [10]. Female study subjects were derived from a community-based cohort of 12,381 residents of Washington Country, Maryland, enrolled in 1974 [4, 8]. A total of 36 baseline (1974) pre-RA females were identified who later developed clinical RA (3–18, median 12 years after entry). The stored (−70°C) baseline sera were anonymously coded and assayed in matched sets of one pre-RA and four CN subjects without knowledge of subject status. The sole rheumatologist in the cohort community had diagnosed and confirmed the RA cases according to American College of Rheumatology (ACR) 1987 revised classification criteria [11] and European League Against Rheumatism (EULAR) recommendations for predisease criteria [12]. A total of 144 CN women were closely matched (4:1) to the 36 pre-RA cases at entry to the cohort. The first batch of study sera was assayed in 1992 on 14 pre-RA and 56 CN females [4, 8, 10]. The second batch of sera was analyzed in 1994 and included the remaining 22 pre-RA and 88 CN subjects [4, 8, 10]. A serum fractionation procedure was developed specifically for this study to permit measurements of 12 steroids in duplicate from 1mL of serum, as described [4].

The CLUE I 1974 entry cohort had enrolled 8,680 males and 12,381 females of Washington County, Maryland, USA. The RAPS database currently includes 90 males (18 pre-RA and 72 CN) and 180 females (36 pre-RA and 144 CN) study subjects, in a ratio of 1 pre-RA : 4 CN. The UICOMP Institutional Review Board approved this research for assurance of confidentiality. Clinical onsets of RA in male and female cases occurred 3 to 20 years (median 12 years) following the 1974 entry into the cohort (1977 to 1994) [8]. No matched CN subject had a diagnosis of RA in the community rheumatologist’s practice. The non-RA cohort CN subjects were matched to pre-RA cases on sex and race (all Caucasians) and usually within one year of age at entry. The selected CN subjects were the closest in chronological sequence of enrollment in the cohort to the pre-RA, analogous to another case-control study [13]. Case or control subjects who had known cancer diagnoses during follow-up were excluded from the RAPS database. Their sera were reserved to study cancer biomarkers, which is the primary purpose of Operation CLUE [14–16].

2.2. Assay Methods for the Comprehensive Panel of Serum Steroids and Hormones. A comprehensive panel of adrenal and sex steroids was assayed in males and females, using previously developed and described methodology [4]. Intra-assay percentile coefficients of variation (% CVs) were all less than 12%, as the measurement criterion for acceptability. Too few batches of assays were performed in the 1992 or 1994 sets to analyze interassay variability among females [4]. The female sera were assayed in separate 1992 (early set) and 1994 (late set) batches. The steroid and hormonal results of the smaller number of 1992 first-set samples (n = 70) were normalized by their mean values to the means of the larger 1994 second-set samples (n = 110), after stratification on pre- and postmenopausal cohort entry status [4]. The number of assayed steroids in the female profile was larger than in males, including the majority of the non-17-hydroxylated steroids (mineralocorticoid pathway), as previously reported [4]. Accordingly, a minority of female subjects had insufficient sera to perform the full panel of the other hormonal assays completed in the males [4]. The minority of missing steroid values in females were imputed, as described below. In both sexes, assay priority was given to cortisol, dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), and prolactin (PRL), which were assayed completely in both male and female subjects.

The male sera (n = 90) were assayed completely in 1996 [4, 8, 10] and those values were analyzed without normalization. In males, sera were sufficient for total assays of two sex hormones, total testosterone (T) and estradiol (E2), two C19 androgenic steroid precursors (DHEA and androstenedione), cortisol, two C21 17-hydroxylated glucocorticoid (GC) precursors (17-hydroxy pregnenolone and 17-hydroxy progesterone), and two pituitary hormones (LH and PRL). In females, sera were sufficient for total assays of cortisol, DHEAS, and three pituitary hormones (FSH, LH, and PRL), but not for the other steroids [10].

2.3. Several Reference Laboratories Performed Immune Assays from 1992 to 1996. Immune assays were performed in males and females by several reference laboratories, using developed and described methodology [8]. As funding was secured during the interval of 1992 to 1996, the study subject sera were periodically utilized for assays of acute phase proteins and cytokines in the referral laboratories. In analyses of female immune biomarker assays, the reported first-set values were normalized to the second-set results by the respective differences in their means, after stratification on pre- and postmenopausal cohort entry status. Although all female cytokine assays were performed at Specialty Laboratories, Inc. (SLI), Santa Monica, CA, in April 1995, results on first- and second-set women were determined in separate runs. For C-reactive protein (CRP) assays, both the first set performed at Northwestern University and the second set, including ASAA results, performed at Boston University [8] were adjusted to the second-set female values for combined analyses.
2.4. Statistical Methods. All steroidal and hormonal (neuroendocrine) values were first transformed to natural logs to improve their symmetry and distributions. Frequency distributions of all values were examined for acceptability of unimodality and symmetry features [4]. Extreme outliers were identified in several variables, particularly the acute phase proteins, which is expected for these sensitive and highly reactive tests [17]. Outliers were assigned to the respective lower and upper ranges in the frequency distributions [18]. The log-transformed NEI values were further converted to z-scores to standardize their variances within the 3 separate subject subsets, that is, early-set females, late-set females, and males [8], and within a merged total data set. The z-score values were almost always distributed ±2 or ±3 standard deviations (SDs).

Multiple imputation (MI) technique was utilized to enter a minority of acceptable values into the 3 respective data sets containing missing values at random [19, 20]. The MI technique was performed using SAS 9.2 Software (SAS Institute Inc., Cary, NC) [21]. Since the data are assumed to have an arbitrary missing data pattern, a Markov chain Monte Carlo (MCMC) method was used when conducting MI with SAS [21]. Then, 10 imputed data sets for each variable were systematically analyzed to derive a single mean value for each of the variables with missing entries, using the IBM SPSS 21.0.0.0 (IBM SPSS, 2012) program AGGREGATE [22]. Frequency distributions of the imputed values were always closely similar to the originally reported values for each variable.

Bivariate and multivariate correlational techniques were performed, including stratification of variables by sex and RA risk status. Logistic regression was used to explore relationships when the outcome was dichotomous. Multiple regression was used when the outcome was interval. Network or pathway interrelations of the NEI systems components were explored using bivariate correlational patterns of the 5 NEI and baseline age variables included in the linear regression models. The dependent and independent bivariate β-coefficients in regression models included age, interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra), androstenedione (adione), testosterone, and cortisol, which were used to approximate the network linkages. Age was always the independent variable in each model. In paired associations, for example, androstenedione and IL-1β, the β-coefficients and p values of the designated dependent variables in the models were entered in the upper panel of a composite correlational matrix. The second encounter of the respective paired correlation was entered into the lower panel. All p values of the respective 10 paired correlations are equal in the upper and lower panels.

Principal component analysis (PCA) was performed using oblique rotation in IBM SPSS 21.0.0.0 (IBM SPSS, 2012) program. The variable loadings on the extracted principal components permit labeling and comparison of matrix patterns among subgroups, for example, females versus males and pre-RA versus CN subjects. Strengths of loadings within components and their differences in patterns when analyzed by total subjects and by subsets of sex and RA risk were evaluated in construction of network diagrams. In this exploratory study, a significance level of p ≤ 0.050 was accepted without adjustment for multiple comparisons [23].

3. Results

3.1. Reported Values of Serum Inflammatory Biomarkers Assayed by Reference Laboratories. Sex differences in serum immunological and inflammatory biomarker values were found for ASAA, sIL-2Rα, and sTNF-R1 (Table 1). The ASAA and sIL-2Rα values were significantly (p < 0.010) greater in females, whereas sTNF-R1 was highly (p < 0.001) significantly greater in males, among the total subjects and separately in the CN and pre-RA subgroups (Table 1). The models did not include IL-6 assays, performed only in females.

3.2. Logistic Regression Models to Identify Independent Inflammatory Biomarkers of Sex. Logistic regression using sex as the dependent outcome variable and age as an independent variable confirmed that the preceding biomarkers independently predicted sex in the total sample when entered either singly or combined (Table 2) as well as in the smaller pre-RA subject sample (data not shown). In the CN subjects, similar results as the total sample were found, except sIL-2Rα prediction was not quite (p = 0.051) significant.

3.3. Reported Serum Steroidal and Hormonal Values Assayed by Reference Laboratories. Highly (p < 0.001) significant sex differences were found in the total sample for each of the steroidal and hormonal values, except to a lesser degree for cortisol (p = 0.012) and not for 17-hydroxyprogesterone (p = 0.176) (Table 3). Logistic regression was next performed using sex as the dependent outcome variable and including baseline age (Table 4). Each of the above-mentioned significant neuroendocrine values (Table 3) independently predicted sex, except for cortisol (p = 0.314) and PRL (p = 0.292). When subjects were stratified into pre-RA and CN subgroups, cortisol predicted sex in the CN (p = 0.025), but not in the smaller sample of pre-RA (p = 0.785) subjects (data not shown).

Of note, when age was included in the logistic regression model, higher 17-hydroxyprogesterone values predicted (p = 0.010) male sex (Table 4). In the total and control subjects, logistic regression models including age confirmed the above-mentioned sexual dimorphic differences in the individual steroidal and hormonal values. In the smaller pre-RA sample (n = 46), the logistic regression model did not execute with the preceding 9 variables but did provide estimates when 17-hydroxyprogrenolone, cortisol, LH, and entry age were excluded. That model yielded significant prediction of the sex outcome for DHEA (p = 0.049), 17-hydroxyprogesterone (p = 0.049), and DHEAS (p = 0.004) and nearly (p = 0.053) significant prediction for androstenedione.

3.4. Steroidal and Hormonal Values Predicting Sexually Dimorphic Inflammatory Biomarkers. To determine if any of the 5 neuroendocrine variables might independently predict levels of the 3 sexually dimorphic serum inflammatory biomarkers (Table 2), each of the latter inflammatory
bimarkers was included as dependent variable in multiple linear regression models (Table 5). As may be expected for sIL-2Rα, which had the least significant ($p = 0.045$) sexual dimorphism, it was predicted only by DHEA in the total subjects ($p = 0.044$) and by 17-hydroxyprogrenolone in pre-RA subjects ($p = 0.015$). Both ASAA ($p = 0.010$) and sTNF-R1 ($p < 0.001$) are strongly dimorphic and both were more frequently predicted by 17-hydroxyprogrenolone and androstenedione in the subset groups (Table 5). The strongest predictor of inflammatory biomarkers was 17-hydroxyprogrenolone with sTNF-R1 in total ($p < 0.001$), control ($p = 0.001$), and pre-RA ($p = 0.030$) subjects (Table 5). The next strongest predictor was androstenedione with highly ($p < 0.001$) significant negative relations to sTNF-R1 in total subjects and controls and with a negative relation to ASAA outcome in pre-RA subjects ($p = 0.015$).

Serum DHEAS was positively correlated with sTNF-R1 in total ($p = 0.044$). Serum DHEAS was positively correlated with sTNF-R1 in total ($p = 0.021$) and control ($p = 0.007$) subjects (Table 5).

Comparison of the pre-RA versus CN regression models revealed a significant ($p = 0.015$) negative beta coefficient of androstenedione with ASAA levels in the pre-RA cases ($B = -0.618$), which was significantly ($p < 0.001$) different from the control ($B = 0.170, p = 0.209$) subjects. A similar contrary sign result was observed for the negative correlation of 17-hydroxyprogrenolone with sIL-2Rα in the pre-RA ($B = -0.595, p = 0.015$), which differed significantly ($p = 0.001$) from the CN ($B = 0.021, p = 0.862$) subjects. No other significant differences were observed between the study groups.

### 3.5. Steroidal and Hormonal Variables Predicting Inflammatory Biomarkers Independently from Serum E2/T Ratio and Subject Sex Status

The ratio of serum estradiol to...
significant predictors of 17-hydroxypregnenolone (Table 2) outcome in the total subjects and eliminated the previous variables were significant independent predictors of ASAA endocrine predictors of sexually dimorphic inflammatory biomarkers, or displace preceding neuroendocrine markers. If those indicators of sex may independently predict levels of testosterone (E2/T) levels and subject sex status were further included in the linear regression models (Table 6) to probe if those indicators of sex may independently predict levels of the inflammatory biomarkers or displace preceding neuroendocrine predictors of sexually dimorphic inflammatory biomarkers observed in Table 5. The E2/T ratio and the sex variable were significant independent predictors of ASAA outcome in the total subjects and eliminated the previous significant predictors of 17-hydroxypregnenolone (p = 0.023) and DHEA (p = 0.013). The sex indicators did not significantly predict sIL-2R levels but eliminated the previous weak prediction by DHEA (p = 0.044); now p = 0.463 (Table 6). The sex variable, but not serum E2/T ratio, is a highly (p < 0.001) significant independent predictor of sTNF-R1 levels in the total subjects (Table 6). It eliminated the previous highly (p < 0.001) significant prediction by 17-hydroxypregnenolone (Table 5); now p = 0.327. However, inclusion of those two sex markers uncovered a significant independent prediction by DHEA (p = 0.015), which was previously not significant (p = 0.872), indicating a profound complexity of the interrelations. Serum androstenedione remained a significant predictor of sTNF-R1 in the total (p = 0.002) and control (p = 0.004) subjects. In the smaller pre-RA subject sample, no variable was an independent predictor of sTNF-R1 levels after addition of the sex markers (Table 6). The persistent significant independent prediction of sTNF-R1 outcome by DHEA and androstenedione in total and control subjects after addition of the E2/T and sex variables suggest prominent neuroendocrine immune (NEI) interactive mechanisms (Table 6).

### Linear Regression of Selected Standardized NEI Systems Biomarkers (Table 7)

In this analysis, the selected immunologic variables were IL-1β and its receptor antagonist (IL-1ra), since a physiological alteration had been found before the premenopausal onset of RA [24]. The selected steroids, androstenedione, testosterone, and cortisol, had differed between pre-RA and matched control subjects in their associations with IL-1β [25]. In the regression models, age is always an independent variable, but the 5 NEI variables (IL-1β, IL-1ra, androstenedione, testosterone, and cortisol) were analyzed as either dependent or independent factors in bivariate correlations within the regression models (Table 7). Variances (R²) explained (VE) in the regression models differed according to the dependent biomarker, being minimal for cortisol in females (0.063 for pre-RA, 0.075 for CN), but moderate for cortisol in males (0.451 for pre-RA, 0.411 for CN). The difference in variances explained reflects stronger cortisol interrelations in males than females. Greater variance (R²) was explained for IL-1β in pre-RA versus CN (0.355 versus 0.031, resp.) and for IL-1ra (0.445 versus 0.027, resp.) (Table 7), reflecting stronger interrelations of those immune biomarkers in pre-RA versus CN subjects.

#### 3.7. Approximated Network Patterns of NEI Variables in Females and Males (Figures 1(a) and 1(b))

The standardized beta (B) coefficients from the linear regression models of the 5 NEI variables and age (Table 7) were used to construct approximated network linkages of pre-RA and CN subjects in females (Figure 1(a)) and males (Figure 1(b)). Weights of the lines of bivariate linkages in the networks were derived from the respective beta coefficients in the linear regression models, and negative correlations are indicated by a terminal “stop sign” circle (−○). Female pre-RA have stronger interrelations of age with androstenedione, IL-1β, and IL-1ra than CN subjects (Figure 1(a)). Male subjects show the strongest linkages of cortisol with testosterone in pre-RA and of cortisol with androstenedione in CN subjects (Figure 1(b)). In contrast, female pre-RA and CN subjects show weakest linkages with cortisol (Figure 1(a)), consistent with their low variances explained in the respective linear regression models (Table 7). Approximated overviews of network patterns can be similarly derived for all female versus male subjects and for all combined pre-RA versus CN subjects (figures not shown). The above-mentioned stronger female interrelations of age, as indicated in Table 7 and Figure 1(a), are visually more evident in the pre-RA versus CN subject networks (figure not shown).

#### 3.8. Principal Components Extraction of the Integrated Neuroendocrine and Immune Variables

The NEI variables which demonstrated sexual dimorphism (Table 6) or those which showed differential patterns of bivariate correlations between pre-RA and CN subjects (Figures 1(a) and 1(b)) were further analyzed in exploratory factor analysis methods [26]. Principal component analysis (PCA) pattern matrices were derived using oblique rotation to determine variable loadings on the extracted factors (components) of comparative subgroups, for example, pre-RA versus CN subjects (Tables 8(a) and 8(b)). This data reduction method can reveal latent relations among the variables. The imputed z-score database standardized to early- and late-set females and to males was used for the PCA. The pattern matrix of 214 CN subjects (Table 8(a)) has 4 principal components, which can be confidently labelled. The 1st component includes heavy loadings of the androgenic anabolic (AA) steroids, which are known to be inversely related to age. The 2nd component has...
Table 3: Steroidal and hormonal values reported by referral laboratory and imputed to full sample sizes.

| Steroid and hormonal statistical values | Controls (N = 216) | Pre-RA cases (N = 54) | All subjects (N = 270)* |
|----------------------------------------|-------------------|-----------------------|------------------------|
|                                        | Females (n = 144) | Males (n = 72)        | Females (n = 36)       | Males (n = 18)         | Females (n = 180) | Males (n = 90) |
| 17-OH pregnenolone                     |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 6.8 ± 0.3         | 11.9 ± 0.8            | 6.8 ± 0.6              | 11.8 ± 1.1            | 6.8 ± 0.3         | 11.9 ± 0.7    |
| Median; IQR                            | 5.7; 4.4–7.9      | 10.2; 7.3–15.2        | 5.7; 4.2–8.8           | 11.0; 8.7–14.6        | 5.7; 4.4–8.2      | 10.2; 7.7–15.0 |
| Dehydroepiandrosterone (DHEA)          |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 18.6 ± 1.0        | 8.5 ± 0.6             | 17.9 ± 1.9             | 7.6 ± 1.0             | 18.5 ± 0.9        | 8.4 ± 0.5     |
| Median; IQR                            | 15.9; 12.5–20.8   | 7.2; 4.8–10.3         | 14.8; 11.5–19.2        | 7.7; 3.9–9.7          | 15.6; 12.4–19.7   | 7.2; 4.7–10.1 |
| 17-OH progesterone                     |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 4.3 ± 0.3         | 5.0 ± 0.3             | 4.3 ± 0.5              | 5.0 ± 0.5             | 4.3 ± 0.3         | 5.0 ± 0.3     |
| Median; IQR                            | 3.0; 1.9–5.7      | 4.7; 3.1–6.3          | 3.6; 1.7–6.1           | 4.5; 3.5–6.0          | 3.1; 1.9–5.9      | 4.7; 3.2–6.2  |
| Androstenedione                         |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 7.6 ± 0.2         | 2.2 ± 0.1             | 6.7 ± 0.4              | 2.2 ± 0.2             | 7.5 ± 0.2         | 2.2 ± 0.1     |
| Median; IQR                            | 7.2; 6.2–8.8      | 2.2; 1.5–2.9          | 6.6; 5.3–8.3           | 2.2; 1.4–3.0          | 7.1; 6.0–8.6      | 2.2; 1.5–2.9  |
| Testosterone (T)                        |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 2.5 ± 0.1         | 18.3 ± 0.8            | 2.4 ± 0.2              | 19.2 ± 1.8            | 2.5 ± 0.1         | 18.5 ± 0.8    |
| Median; IQR                            | 2.3; 1.8–2.9      | 17.4; 13.7–23.3       | 2.3; 1.8–2.9           | 17.8; 13.3–24.3       | 2.3; 1.8–2.9      | 17.8; 13.6–23.5 |
| Estradiol (E2)                          |                   |                       |                        |                        |                   |               |
| Mean (pmol/L) ± SE                     | 229.5 ± 18.2      | 65.4 ± 2.9            | 251 ± 60.7             | 69.7 ± 6.0            | 233.0 ± 19.7      | 66.2 ± 2.6    |
| Median; IQR                            | 176; 80–278       | 66.0; 48.0–80.3       | 168; 83–276            | 68; 49.0–84.3         | 173; 81–278       | 66.0; 48.0–81.0 |
| E2/T ratio (×10³)                       |                   |                       |                        |                        |                   |               |
| Mean ± SE                              | 123.0 ± 16.5      | 4.1 ± 0.3             | 134.0 ± 36.1           | 4.1 ± 0.5             | 125.2 ± 15.0      | 4.1 ± 0.2     |
| Median; IQR                            | 80.2; 37.6–138    | 3.4; 2.5–5.0          | 76.5; 277–151          | 4.0; 2.7–4.9          | 78.8; 35.4–138    | 3.5; 2.6–5.0  |
| DHEA sulfate (DHEAS)                    |                   |                       |                        |                        |                   |               |
| Mean (µmol/L) ± SE                     | 3.0 ± 0.2         | 7.3 ± 0.4             | 2.5 ± 0.3              | 7.5 ± 1.1             | 2.9 ± 0.1         | 7.3 ± 0.4     |
| Median; IQR                            | 2.6; 1.6–3.9      | 6.8; 4.8–8.8          | 2.3; 1.5–3.5           | 6.2; 3.8–11.0         | 2.5; 1.6–3.8      | 6.8; 4.6–8.9  |
| Cortisol                               |                   |                       |                        |                        |                   |               |
| Mean (nmol/L) ± SE                     | 233.4 ± 11.8      | 291.1 ± 18.7          | 245.2 ± 24.6           | 272.8 ± 35.4          | 236.8 ± 10.8      | 285.5 ± 16.7  |
| Median; IQR                            | 205; 155–285      | 255; 186–382          | 241; 143–329           | 257; 161–381          | 216; 155–286      | 255; 184–369  |
| Luteinizing hormone (LH)               |                   |                       |                        |                        |                   |               |
| Mean (IU/L) ± SE                        | 23.4 ± 1.8        | 5.9 ± 0.3             | 23.5 ± 3.4             | 5.8 ± 0.7             | 23.4 ± 1.6        | 5.9 ± 0.3     |
| Median; IQR                            | 15.7; 5.4–39.5    | 5.1; 4.0–6.9          | 19.6; 4.3–36.2         | 5.5; 4.0–7.2          | 17.1; 5.3–37.9    | 5.1; 4.0–7.0  |
| Prolactin (PRL)                         |                   |                       |                        |                        |                   |               |
| Mean (µg/L) ± SE                        | 11.9 ± 0.5        | 7.0 ± 0.4             | 11.0 ± 0.8             | 8.0 ± 1.0             | 11.7 ± 0.4        | 7.2 ± 0.4     |
| Median; IQR                            | 10.4; 8.0–13.4    | 6.1; 4.6–9.0          | 9.5; 8.1–13.3          | 7.6; 4.0–11.4         | 10.1; 8.1–13.4    | 6.3; 4.6–9.7  |

*Significant (p < 0.001) differences in values between total females and males, except for cortisol (p = 0.012) and 17-hydroxypregesterone (p = 0.176).

heavy loadings of the sexual dimorphic cytokine receptors. The 3rd component includes heavy loadings of IL-1β and its receptor antagonist (IL-1ra), as an expected relation. The 4th component of CN subjects includes only cortisol and yields total variance explained (VE) of 72.7% (Table 8(a)). In contrast, the pattern matrix of pre-RA subjects had only 3 components extracted. The 1st includes significant loadings of the AA steroids, as noted in CN subjects, but also includes IL-1β and cortisol. As found in the CN subjects, the 2nd component has heavy loading of the sexually dimorphic
Table 4: Logistic regression model of sex outcome including steroidal and hormonal variables, but not testosterone and estradiol levels.

| Variables in the model | Total (N = 270) | Controls (N = 216) |
|------------------------|-----------------|--------------------|
|                        | Wald | p values | Wald | p values |
| 17-OH pregnenolone (17-OHP5) | 6.686 | 0.010 | 2.586 | 0.108 |
| Dehydroepiandrosterone (DHEA) | 6.572 | 0.010 | 2.305 | 0.129 |
| 17-OH progesterone (17-OH P4) | 0.899 | 0.343 | 0.666 | 0.415 |
| Androstenedione | 6.600 | 0.010 | 5.169 | 0.023 |
| DHEA sulfate (DHEAS) | 12.708 | <0.001 | 9.596 | 0.002 |
| Cortisol | 1.012 | 0.314 | 5.045 | 0.025 |
| Luteinizing hormone (LH) | 7.076 | 0.008 | 3.576 | 0.059 |
| Prolactin (PRL) | 1.110 | 0.292 | 2.305 | 0.129 |
| Age at entry | 2.338 | 0.126 | 1.098 | 0.295 |
| Constant | 0.016 | 0.899 | 0.498 | 0.480 |

Logistic regression models of dependent sex outcome did not execute when either testosterone or estradiol values were entered.

1 df for each variable entered in block.

4. Discussion

Causation mechanisms in rheumatoid arthritis are profoundly complex involving multiple genetic, age-related, sex, environmental, microvascular, neuroendocrine, and particularly immune or inflammatory pathways [27–30]. Sex hormones and sexual dimorphism control various body functions and may have predisposing or protective influences on physiological pathways or pathological processes. Dys-regulations of the neuroendocrine and immune or inflammatory (NEI) systems are suspected to play a role in the development or progression of RA, in association with responses of the microvascular system [31, 32]. Differences are reported in blood levels or frequencies of suspected causal factors between affected patients and comparison subjects and differences have been observed even before the clinical onset of symptoms (pre-RA) [24]. However, such reported alterations were usually found in only a particular pathway or systemic category [24]. Analyses of cross talk between age, sex-related factors, hormones, and immune or inflammatory serum biomarkers have not previously been reported in pre-RA cases and CN subjects, to our knowledge.

In the current multivariable analyses, examples of significant sexual dimorphisms were identified in components of the NEI systems (Table 6). Adrenal androgens (DHEA and androstenedione) significantly interacted with the sexually
Table 5: Multiple regression models of serum inflammatory biomarker outcomes including steroidal and hormonal variables that had predicted sex.

| Variables in the model of total subjects | ASAA outcome (N = 142) | sIL-2Rα outcome (N = 159) | sTNF-R1 outcome (N = 159) |
|----------------------------------------|------------------------|--------------------------|--------------------------|
|                                        | Beta* | p values | Beta* | p values | Beta* | p values |
| 17-OH P5                               | −0.216 | 0.023 | −0.116 | 0.268 | 0.334 | <0.001 |
| DHEA                                   | 0.286 | 0.013 | 0.200 | 0.044 | −0.013 | 0.872 |
| Adione                                 | 0.022 | 0.853 | −0.032 | 0.732 | −0.387 | <0.001 |
| DHEAS                                  | −0.147 | 0.129 | −0.147 | 0.130 | 0.177 | 0.021 |
| LH                                     | 0.084 | 0.365 | 0.030 | 0.772 | −0.094 | 0.255 |
| Entry age                              | 0.226 | 0.016 | −0.102 | 0.292 | 0.006 | 0.936 |

| Variables in the model of control subjects | ASAA outcome (n = 113) | sIL-2Rα outcome (n = 126) | sTNF-R1 outcome (n = 126) |
|-------------------------------------------|------------------------|--------------------------|--------------------------|
|                                          | Beta* | p values | Beta* | p values | Beta* | p values |
| 17-OH P5                                 | −0.257 | 0.017 | 0.021 | 0.862 | 0.303 | 0.001 |
| DHEA                                     | 0.198 | 0.146 | 0.204 | 0.073 | 0.046 | 0.604 |
| Adione                                   | 0.170 | 0.209 | −0.092 | 0.390 | −0.450 | <0.001 |
| DHEAS                                    | −0.185 | 0.092 | −0.193 | 0.096 | 0.241 | 0.007 |
| LH                                       | 0.054 | 0.613 | 0.088 | 0.470 | −0.037 | 0.703 |
| Entry age                                | 0.199 | 0.054 | −0.054 | 0.631 | 0.038 | 0.668 |

| Variables in the model of pre-RA subjects | ASAA outcome (n = 29) | sIL-2Rα outcome (n = 33) | sTNF-R1 outcome (n = 33) |
|--------------------------------------------|------------------------|--------------------------|--------------------------|
|                                           | Beta | p values | Beta* | p values | Beta* | p values |
| 17-OH P5                                  | 0.127 | 0.533 | −0.595 | 0.015 | 0.479 | 0.030 |
| DHEA                                      | 0.496 | 0.015 | 0.367 | 0.094 | −0.193 | 0.313 |
| Adione                                    | −0.618 | 0.015 | 0.123 | 0.552 | −0.198 | 0.272 |
| DHEAS                                     | −0.166 | 0.417 | 0.031 | 0.873 | 0.022 | 0.896 |
| LH                                        | 0.155 | 0.364 | −0.237 | 0.254 | −0.231 | 0.208 |
| Entry age                                 | 0.210 | 0.307 | −0.130 | 0.537 | −0.077 | 0.671 |

*Standardized beta coefficients from linear regression of log-transformed, reported NEI biomarkers.

dimorphic cytokine receptors (sIL-2Rα and sTNF-R1), both in pre-RA in and CN subjects. Such cross talk may likely reflect normal underlying physiological control mechanisms in the NEI systems. In contrast, interactions of other NEI systems components differed significantly between the pre-RA and CN subjects. In PCA, IL-1β and cortisol strongly loaded with the AA steroids in the 1st component by only pre-RA, not CN, subjects (Tables 8(a) and 8(b), Figures 1(a) and 1(b)). This new finding may have been contributed by previously reported lower androstenedione and cortisol levels in female pre-RA versus CN women [4]. In previous bivariate analyses [33], combined low serum cortisol (<140 nmol/L) and low testosterone (<10 nmol/L) levels were an independent risk marker for clinical onset of RA in males. In this current multivariate analysis, the association of cortisol with testosterone was stronger in male pre-RA versus CN subjects (Table 7, Figure 1(b)).

In other bivariate analyses [34], basal steroidogenesis was considered normal in pre-RA postmenopausal women and men compared to CN subjects. That result conforms generally to the current multivariate analysis; that is, the age-related AA steroids were extracted as the 1st component in PCA of both CN (Table 8(a)) and pre-RA (Table 8(b)) subjects. Loadings of the individual AA compounds were also similar. A matrix pattern difference was the additional extraction of cortisol in the 1st component only in the pre-RA cases, although it is not age-related, as are the AA steroids. The pre-RA findings in PCA may be consistent with the above-mentioned association of lower androstenedione and cortisol levels observed in pre-RA women [4].

Lower serum levels of adrenal androgens (AA) were reported in premenopausal women with RA not treated with glucocorticoids [1, 2], which also correlated with lower serum cortisol levels [4]. Early menopause was reported to be an independent predictor of RA [3]. Intrinsically low or insufficient adrenocortical and ovarian function was proposed in a minority of premenopausal onset RA patients [4], based upon the preceding findings [1–3]. In contrast, postmenopausal women revealed normal steroidogenesis before clinical onset of RA [34]. One may hypothesize that a polymorphism in adrenal and gonadal function occurs in women and may be related to predisposition and onset age of RA. Limited data
Table 6: Multiple regression model of serum inflammatory biomarker outcomes including variables that predicted sex plus E2/T ratio and actual sex status.

| Independent variables in total subjects | ASAA outcome (N = 142) | sIL-2Ra outcome (N = 159) | sTNF-R1 outcome (N = 159) |
|----------------------------------------|------------------------|---------------------------|---------------------------|
|                                        | Beta*                  | p values                  | Beta*                    | p values                  | Beta*                    | p values                  |
| 17-OH P5                               | −0.039                 | 0.725                     | 0.021                    | 0.863                     | 0.088                    | 0.327                     |
| DHEA                                   | −0.113                 | 0.519                     | 0.093                    | 0.463                     | 0.228                    | 0.015                     |
| Adione                                 | 0.080                  | 0.490                     | −0.091                   | 0.385                     | −0.241                   | 0.002                     |
| DHEAS                                  | 0.141                  | 0.323                     | 0.012                    | 0.928                     | −0.166                   | 0.084                     |
| LH                                     | 0.092                  | 0.312                     | 0.016                    | 0.887                     | 0.052                    | 0.528                     |
| E2/T ratio                             | 0.270                  | < 0.001                   | −0.040                   | 0.694                     | −0.029                   | 0.696                     |
| Sex (F = 0, M = 1)                     | −0.434                 | 0.044                     | −0.333                   | 0.075                     | 0.682                    | < 0.001                   |
| Entry age                               | 0.194                  | 0.032                     | −0.043                   | 0.672                     | −0.066                   | 0.371                     |

| Independent variables in control subjects | ASAA outcome (n = 113) | sIL-2Ra outcome (n = 126) | sTNF-R1 outcome (n = 126) |
|--------------------------------------------|------------------------|---------------------------|---------------------------|
|                                            | Beta*                  | p values                  | Beta*                    | p values                  | Beta*                    | p values                  |
| 17-OH P5                                  | −0.113                 | 0.377                     | 0.101                    | 0.456                     | 0.085                    | 0.380                     |
| DHEA                                       | −0.094                 | 0.631                     | 0.143                    | 0.296                     | 0.230                    | 0.024                     |
| Adione                                     | 0.173                  | 0.174                     | −0.110                   | 0.356                     | −0.257                   | 0.004                     |
| DHEAS                                      | 0.089                  | 0.622                     | −0.102                   | 0.519                     | −0.110                   | 0.341                     |
| LH                                         | 0.099                  | 0.339                     | 0.063                    | 0.622                     | 0.085                    | 0.361                     |
| E2/T ratio                                 | 0.296                  | 0.002                     | −0.074                   | 0.515                     | 0.006                    | 0.942                     |
| Sex (F = 0, M = 1)                         | −0.321                 | 0.215                     | −0.229                   | 0.278                     | 0.692                    | < 0.001                   |
| Entry age                                  | 0.164                  | 0.100                     | 0.004                    | 0.970                     | −0.053                   | 0.537                     |

| Independent variables in pre-RA subjects  | ASAA outcome (n = 29) | sIL-2Ra outcome (n = 33) | sTNF-R1 outcome (n = 33) |
|-------------------------------------------|-----------------------|--------------------------|--------------------------|
|                                            | Beta*                 | p values                 | Beta*                    | p values                 | Beta*                    | p values                 |
| 17-OH P5                                  | 0.296                 | 0.269                     | −0.105                   | 0.762                     | −0.078                   | 0.786                     |
| DHEA                                       | 0.071                 | 0.892                     | 0.053                    | 0.893                     | 0.136                    | 0.671                     |
| Adione                                     | −0.589                | 0.115                     | −0.096                   | 0.729                     | −0.131                   | 0.545                     |
| DHEAS                                      | 0.015                 | 0.962                     | 0.306                    | 0.241                     | −0.283                   | 0.193                     |
| LH                                         | 0.049                 | 0.835                     | −0.295                   | 0.240                     | −0.111                   | 0.584                     |
| E2/T ratio                                 | 0.018                 | 0.940                     | 0.316                    | 0.326                     | −0.476                   | 0.073                     |
| Sex (F = 0, M = 1)                         | −0.734                | 0.215                     | −0.584                   | 0.224                     | 0.399                    | 0.295                     |
| Entry age                                  | 0.198                 | 0.432                     | −0.145                   | 0.519                     | −0.118                   | 0.506                     |

* Standardized beta coefficients from linear regression of log-transformed, reported NEI biomarkers.

are available on such intrinsic hormonal functions before or after RA onset. Further investigation is needed to understand neuroendocrine and immune (NEI) relations to RA.

The current multivariable NEI systems analyses revealed sexual dimorphism in the interaction of IL-1β with its receptor antagonist (IL-1ra). A significantly stronger correlation was found in females than in males as well as in CN than in pre-RA subjects (Table 7, Figures 1(a) and 1(b)). In a previous bivariate analysis [35], perturbations in serum levels of interleukin-1 beta (IL-1β) and IL-1 receptor antagonist (IL-1ra) were found before onset of clinical rheumatoid arthritis (pre-RA) in women with younger onset ages. Eight of the 10 sera tested from younger pre-RA women were positive for IL-1 system perturbation versus 3 (9.7%) of 31 CN (p < 0.001, Fisher’s exact test). Perturbation of the IL-1 system was defined as either an elevated serum IL-1β level (1.2+ pg/mL) without elevation of IL-1ra or a definitely low serum IL-1ra level (<300 pg/mL). In the complex interactions of many NEI factors, as noted in the IL-1 system, the current multivariate analyses help to focus on particular linkages and to estimate comparative strengths of the various correlations.

The observed differences in multivariate networks and PCA pattern matrices of pre-RA versus CN subjects will require further confirmatory statistical analyses [26] as well as independent controlled investigation. However, bivariate correlational findings in scatterplots support the above findings. An impressive gradient of regressions of IL-1β (x-axis) and IL-1ra (y-axis) is found among the sex and subject groups:
Results of current network analyses must be qualified, as the differences found between pre-RA and CN subjects, the interleukin-1 system may be of greater interest as a predisposing risk factor to RA or as an example of physiological dysregulation in NEI biomarkers. In females, those differences may be related to androstenedione (Figures 1(a) and 1(b)). In males, enhanced correlations of cortisol with testosterone in the pre-RA subjects (Figure 1(a)) and of cortisol with androstenedione in the control group (Figure 1(b)) may reflect unrecognized control mechanisms and deserve further investigation.

Since the earlier incorporation of multivariate analytic techniques in an integrated overview of neuroendocrine factors in relation to RA risk, 10 years ago [24], the need for such methodological approach is now intensified to gain penetrating knowledge. Univariate and bivariate analytic techniques can identify differences in systems, but the
complexity of multiple interactive NEI factors requires more advanced data reduction and differential methods [36]. The current effort is a preliminary probe of interplay of NEI factors which may contribute to risk of developing RA and the significant differences need to be confirmed in further penetrating analytical investigation.

5. Conclusion

Current multivariate analyses identified 3 sexually dimorphic inflammatory biomarkers: ASAA; sIL-2Rα; and sTNF-R1, which correlated with the detected sexually dimorphic steroids. Significant associations of sTNF-R1 with androstenedione were observed in total and control subjects, with or without inclusion of the sex category or the ratio of serum E2/T in the regression models. Principal component analysis showed differential loadings of IL-1β and cortisol in the 1st component of the matrix patterns of pre-RA versus CN subjects. After stratification by sex and risk of developing RA, other differences in the interplay of components in the NEI systems were observed, which deserve further investigation.

Conflict of Interests

The authors declare that no existing or potential conflict of interests exists.

Acknowledgments

Baseline subject entry demographic data and sera were provided by The CLUE Study, Campaign Against Cancer and Stroke, funded in 1974 by Grant CA 118949 from the National Cancer Institute. Steroidal and hormonal assays
were performed in the laboratory of Dr. Robert T. Chatterton, Northwestern University (NWU), Feinberg School of Medicine, Chicago, IL, USA, and the acute phase proteins, ASAA and CRP, were performed in the laboratory of Dr. Jean D. Sipe, Department of Biochemistry (Retired), Boston University School of Medicine, Boston, MA, USA. Dr. Huaping Wang performed the multiple imputations of missing values in stratified data sets of early-set females, late-set females, and males and a combined total file. Marina Palakeel is thanked for her technical assistance. This project was supported by the Department of Medicine, University of Illinois College of Medicine at Peoria, a gift from the MTM Foundation, and financial support from the Research Open Access Publishing (ROAAP) Fund of the University of Illinois at Chicago towards the open access publishing fee for this paper.

References

[1] M. Cutolo, L. Foppiani, C. Prete et al., “Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids,” *Journal of Rheumatology*, vol. 26, no. 2, pp. 282–288, 1999.

[2] R. Imrich, M. Vigas, J. Rovensky, J. C. Aldag, and A. T. Masi, “Adrenal plasma steroid relations in glucocorticoid-naive premenopausal rheumatoid arthritis patients during insulin-induced hypoglycemia test compared to matched normal control females,” *Endocrine Regulations*, vol. 43, no. 2, pp. 65–73, 2009.

[3] M. Pikker, U. Bergström, J.-Å. Nilsson, L. Jacobsson, and C. Turesson, “Early menopause is an independent predictor of rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 71, no. 3, pp. 378–381, 2012.

[4] A. T. Masi, K. B. Elmore, A. A. Rehman, R. T. Chatterton, N. J. Goertzen, and J. C. Aldag, “Lower serum androstenedione levels in pre-rheumatoid arthritis versus normal control women: correlations with lower serum cortisol levels,” *Autoimmune Diseases*, vol. 2013, Article ID 593493, 13 pages, 2013.

[5] I. Kushner, “Regulation of the acute phase response by cytokines,” *Perspectives in Biology and Medicine*, vol. 36, no. 4, pp. 611–622, 1993.

[6] M. Y. Abeywardena, W. R. Leifert, K. E. Warnes, J. N. Varghese, and R. J. Head, “Cardiovascular biology of interleukin-6,” *Current Pharmaceutical Design*, vol. 15, no. 15, pp. 1809–1821, 2009.

[7] M. A. van Leeuwen, J. Westra, P. C. Limburg, P. L. van Riel, and M. H. Van Rijswijk, “Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study,” *Annals of the Rheumatic Diseases*, vol. 54, no. 8, pp. 674–677, 1995.

[8] A. T. Masi, A. A. Rehman, K. B. Elmore, and J. C. Aldag, “Serum acute phase protein and inflammatory cytokine network correlations: comparison of a pre-rheumatoid arthritis and non-rheumatoid arthritis community cohort,” *Journal of Innate Immunity*, vol. 5, no. 2, pp. 100–113, 2013.

[9] M. M. J. Nielen, D. van Schaardenburg, H. W. Reesink et al., “Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 50, no. 8, pp. 2423–2427, 2004.

[10] A. T. Masi, A. A. Rehman, R. T. Chatterton et al., “Controlled cohort study of serum gonadal and adrenocortical steroid levels in males prior to onset of rheumatoid arthritis (pre-RA): a comparison to pre-RA females and sex differences among the study groups,” *International Journal of Rheumatology*, vol. 2013, Article ID 284145, 11 pages, 2013.

[11] F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 31, no. 3, pp. 315–324, 1988.

[12] D. M. Gerlag, K. Raza, L. G. Van Baarsen et al., “EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis,” *Annals of the Rheumatic Diseases*, vol. 71, no. 5, pp. 638–641, 2012.

[13] K. T. Jørgensen, A. Wiik, M. Pedersen et al., “Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors,” *Annals of the Rheumatic Diseases*, vol. 67, no. 6, pp. 860–866, 2008.

[14] K. J. Helzlsouer, A. J. Alberg, G. B. Gordon et al., “Serum gonadotropins and steroid hormones and the development of ovarian cancer,” *Journal of the American Medical Association*, vol. 274, no. 24, pp. 1926–1930, 1995.

[15] N. Rothman, K. P. Cantor, A. Blair et al., “A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues,” *The Lancet*, vol. 350, no. 9073, pp. 240–244, 1997.

[16] A. J. Alberg, G. B. Gordon, S. C. Hoffman, G. W. Comstock, and K. J. Helzlsouer, “Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 9, no. 5, pp. 517–521, 2000.

[17] G. Cunnane, S. Grehan, S. Geoghegan et al., “Serum amyloid A in the assessment of early inflammatory arthritis,” *Journal of Rheumatology*, vol. 27, no. 1, pp. 58–63, 2000.

[18] W. J. Dixon and J. W. Tukey, “Approximate behavior of the distribution of Winsorized t (Trimming/Winsorization 2),” *Technometrics*, vol. 10, no. 1, pp. 83–98, 1968.

[19] B. D. Rubin, *Multiple Imputation for Nonresponse in Surveys*, John Wiley & Sons, New York, NY, USA, 1987.

[20] J. L. Schafer, “Multiple imputation: a primer,” *Statistical Methods in Medical Research*, vol. 8, no. 1, pp. 3–15, 1999.

[21] SAS Institute, *SAS/STAT 9.2 User’s Guide*, Cary, NC, USA, 2nd edition, 2009, http://support.sas.com/documentation/cdl/en/statug/63033/PDF/default/statug.pdf.

[22] IBM SPSS 21.0.0.0, *Statistics 21 Command Syntax Reference*, (IBM SPSS, 2012) Program, AGGREGATE, Chicago, Ill, USA, 2012.

[23] K. J. Rothman, “No adjustments are needed for multiple comparisons,” *Epidemiology*, vol. 1, no. 1, pp. 43–46, 1990.

[24] A. T. Masi and J. C. Aldag, “Integrated neuroendocrine immune risk factors in relation to rheumatoid arthritis: should rheumatologists now adopt a model of a multiyear, presymptomatic phase?” *Scandinavian Journal of Rheumatology*, vol. 34, no. 5, pp. 342–352, 2005.

[25] A. T. Masi, J. C. Aldag, R. T. Chatterton, and R. L. Malamet, “Basal serum IL-1 beta correlations with glucocorticoid precursor and sex steroid levels differed significantly in men and women before onset of rheumatoid arthritis (pre-RA) versus their matched controls,” *Arthritis and Rheumatism*, vol. 50, no. 9, pp. S352–S353, 2004.
[26] R. L. Gorsuch, “Exploratory factor analysis: its role in item analysis,” *Journal of Personality Assessment*, vol. 68, no. 3, pp. 532–560, 1997.

[27] K. S. Kanik and R. L. Wilder, “Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy,” *Rheumatic Disease Clinics of North America*, vol. 26, no. 4, pp. 805–823, 2000.

[28] A. T. Masi, J. C. Aldag, and R. T. Chatterton, “Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences,” *Annals of the New York Academy of Sciences*, vol. 1069, pp. 223–235, 2006.

[29] R. H. Straub, “Rheumatoid arthritis—a neuroendocrine immune disorder: glucocorticoid resistance, relative glucocorticoid deficiency, low-dose glucocorticoid therapy, and insulin resistance,” *Arthritis Research & Therapy*, vol. 16, supplement 2, article II, 2014.

[30] K. Stark, R. H. Straub, J. Rovenský, S. Blažičková, G. Eiselt, and M. Schmidt, “CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women,” *Arthritis Research & Therapy*, vol. 17, article 56, 2015.

[31] A. T. Masi, J. C. Aldag, and J. W. Jacobs, “Rheumatoid arthritis: neuroendocrine immune integrated physiopathogenetic perspectives and therapy,” *Rheumatic Disease Clinics of North America*, vol. 31, no. 1, pp. 131–160, 2005.

[32] E. Calcagni and I. Elenkov, “Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases,” *Annals of the New York Academy of Sciences*, vol. 1069, pp. 62–76, 2006.

[33] A. T. Masi, J. C. Aldag, R. T. Chatterton et al., “Independent risk markers (RMs) for RA onset in males include rheumatoid arthritis (RA) in a first degree relative (FDR+); rheumatoid factor (RF+); combined low serum cortisol and testosterone (low C&T); and heavy cigarette smoking (CS 30+/d),” *Arthritis & Rheumatism*, vol. 43, no. 9, abstract S70, 2000.

[34] A. T. Masi, J. C. Aldag, R. L. Malamet, and J. B. Peter, “Basal steroidogenesis was normal before clinical onset of rheumatoid arthritis (pre-RA) in postmenopausal women and men, despite marked differences by gender, and gender dimorphisms of correlations with TNF-alpha,” *Arthritis & Rheumatism*, vol. 48, no. 9, p. S344, 2003.

[35] A. T. Masi, J. C. Aldag, R. L. Malamet, and J. B. Peter, “Perturbations in serum levels of interleukin-1 beta (IL-1beta) and IL-1 receptor antagonist (IL-1Ra) before clinical rheumatoid arthritis (pre-RA) in women with younger versus older onsets,” *Arthritis and Rheumatism*, vol. 46, no. 9, abstract S101, 2002.

[36] S. Soliman and M. Heiner, “A unique transformation from ordinary differential equations to reaction networks,” *PLoS ONE*, vol. 5, no. 12, Article ID e14284, 2010.